Anastrozol 1mg 50 tablets Estrogen blocker
$110.00 – $495.00
Anastrozol is indicated for the:
• Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women.
• Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
Anastrozole should not be used in premenopausal women. The menopause should be defined biochemically (luteinising-hormone [LH], follicle stimulating hormone [FSH], and/or oestradiol levels) in any patient where there is doubt about menopausal status. There are no data to support the use of Anastrozole with LHRH analogues.
Co-administration of tamoxifen or oestrogen-containing therapies with Anastrozole should be avoided as this may diminish its pharmacological action (see section 4.5 and 5.1).
Effect on bone mineral density
As Anastrozole lowers circulating estrogen levels it may cause a reduction in bone mineral density with a possible consequent increased risk of fracture (see section 4.8).
Women with osteoporosis or at risk of osteoporosis, should have their bone mineral density formally assessed at the commencement of treatment and at regular intervals thereafter. Treatment or prophylaxis for osteoporosis should be initiated as appropriate and carefully monitored. The use of specific treatments, e.g., bisphosphonates, may stop further bone mineral loss caused by Anastrozol in postmenopausal women and could be considered (see section 4.8).
Anastrozole has not been investigated in breast cancer patients with moderate or severe hepatic impairment. Exposure to anastrozole can be increased in subjects with hepatic impairment (see section 5.2); administration of Anastrozole in patients with moderate and severe hepatic impairment should be performed with caution (see section 4.2). Treatment should be based on a benefit-risk evaluation for the individual patient.
Single product, 2 Sets, 3 Sets, 4 Sets, 5 Sets bulk price resellers